CD274 and small cell lung carcinoma: The CASPIAN and IMpower133 studies demonstrated the effectiveness of combining a PD-L1 inhibitor with chemotherapy in first-line treatment for ES-SCLC, achieving a median OS of approximately 13 months.14,15 However, there is still no evidence supporting ICI use as second-line therapy for recurrent LS-SCLC.